HEPA vs DBVT vs HALO vs IMVT

Halozyme Therapeutics, Inc.

(HALO) offers the better valuation at 25. 5x trailing P/E (8. 0x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -100. 0% for Hepion Pharmaceuticals, Inc. (HEPA). Over 10 years, the gap is even starker: HALO returned +559. 7% versus HEPA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hepion Pharmaceuticals, Inc.

(HEPA) is the lower-risk stock at -0. 91β versus Immunovant, Inc. 's 1. 36β — meaning IMVT is approximately -250% more volatile than HEPA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Hepion Pharmaceuticals, Inc.

grew EPS 99. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — HALO leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hepion Pharmaceuticals, Inc.

(HEPA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 91)). Both have compounded well over 10 years (HEPA: -100. 0%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HEPA is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.